Good news - NS1009 transdermal patch has been approved by the US FDA IND

On July 17, 2024 Beijing time, the company's independently developed NS1009 transdermal patch officially obtained the approval of the New Drug Clinical Research Application (IND) from the US Food and Drug Administration (FDA). This milestone victory not only demonstrates the outstanding achievements of New Link Pharmaceuticals in the field of innovative drug research and development, but also marks a solid step towards the forefront of pharmaceutical technology.

NS1009 transdermal patch, as our independently developed improved innovative drug, brings a new treatment option for patients with specific indications with its unique and innovative transdermal delivery method. The original intention of designing this drug is to tailor it for patients who require long-term and stable drug treatment, achieving sustained and effective drug release through direct absorption through the skin. This revolutionary design not only greatly improves the convenience and comfort of medication for patients, but also brings them more humane treatment options.

The FDA's IND approval this time is not only a high recognition of the outstanding strength of the New Frontier Medical research team, but also the best proof of our firm belief and unremitting efforts in innovation and dedication to improving the quality of life of patients worldwide over the years.

Looking ahead to the future, Novastage Pharmaceuticals will take this IND approval as an opportunity to continue to deepen its focus on innovative drug research and development, and constantly explore new boundaries in pharmaceutical technology. We will uphold our original intention, continue to bring more and better treatment options to patients around the world, contribute our wisdom and strength to their health and well-being, and write a more brilliant chapter for New Frontier Medicine!